Infliximab Cost

Infliximab is a monoclonal antibody that is administered intravenously to treat a number of chronic inflammatory conditions.

Evolution of infliximab therapy – John K. Marshall, MD

Mechanism of action

Infliximab works by blocking the functional activity of a cell-signaling protein (cytokine) called tumor necrosis factor alpha (TNF-α), which is a substance that plays a key role in inflammation. Using infliximab to inhibit TNF-α does not cure the inflammatory disease; however, it reduces the signs and symptoms of inflammation that arise in patients with such conditions.

Indications

Also known by the brand name Remicade, infliximab first received approval from the United States Food and Drug Administration (FDA) in August 1998 for the treatment of Crohn’s disease. In 2004, this approval by the FDA was extended to rheumatoid arthritis and, in 2005, to ulcerative colitis (UC). Infliximab also received approval for the treatment of pediatric Crohn’s disease in 2006 and pediatric UC in 2011.

Active Crohn's disease failing to respond to therapy

Infliximab is currently approved in the United Kingdom for the treatment of patients with severe and active Crohn’s disease that has failed to respond to a full course of treatment with a corticosteroid and/or immunosuppressant. This treatment is also available for those who are intolerant to these therapies or have medical contraindications for them.

For these patients, infliximab is administered by intravenous infusion at a dosage of 5 milligrams (mg) per kilograms (kg) of body weight (5mg/kg) over a period of two hours. This is followed by a repeat infusion two weeks later. If symptoms do not improve after these two doses, no further treatment is administered.

In cases where the disease does respond to infliximab, patients receive maintenance treatments of 5 mg/kg infusions 6 weeks after the first dose, with infusions then following every 8 weeks. For adults, dose escalation may be an option if the disease stops responding.

Active fistulizing Crohn's

Patients with active and fistulizing Crohn’s disease that has failed to respond to a full course of conventional therapies such as drainage, antibiotics, and an immunosuppressant, can also be prescribed infliximab in the United Kingdom.

For these patients, infliximab is infused at a dose of 5 mg/kg for 2 hours with repeat infusions two and six weeks later. In cases where the disease fails to respond after these three doses, no further infliximab infusions are given.

For those with a disease that does respond to infliximab treatment, maintenance infusions of 5 mg/kg may be given every eight weeks or a re-administration treatment of 5 mg/kg may be given when symptoms recur, followed by the same infusion every 8 weeks. For adults, dose escalation may be considered if their disease has stopped responding.

Severe and active Crohn's in the pediatric population

Infliximab can also be used to treat patients between the ages of 6 and 17 years with severe and active Crohn’s disease that has failed to respond to conventional therapies including primary nutrition therapy, an immunomodulatory drug and a corticosteroid, or those who are intolerant or have medical contraindications for these therapies.

For these patients, intravenous infusions of 5 mg/kg are given followed by repeat infusions two and six weeks later, and then every 8 weeks.

Cost

The cost of a 100 mg vial of infliximab in the United Kingdom is £419.62, excluding VAT, and $987.56 in the United States.

Since the dose is adjusted according to a person’s body weight, the cost of treatment varies between individuals. The cost for someone weighing 73 kg, for example, would be £1,678 in the United Kingdom and $3,950.24 in the United States, because four 100 mg vials would be needed to administer a dose of 365 mg. With an assumed administration cost per infusion of £258 and $617, the cost of two infusions would be around £3,872 or $9,107. To continue therapy at the standard dose over a total of twelve months, the cost would be around £12,584 or $29,643.

References

Further Reading

Last Updated: May 11, 2021

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2021, May 11). Infliximab Cost. News-Medical. Retrieved on July 25, 2021 from https://www.news-medical.net/health/Infliximab-Cost.aspx.

  • MLA

    Robertson, Sally. "Infliximab Cost". News-Medical. 25 July 2021. <https://www.news-medical.net/health/Infliximab-Cost.aspx>.

  • Chicago

    Robertson, Sally. "Infliximab Cost". News-Medical. https://www.news-medical.net/health/Infliximab-Cost.aspx. (accessed July 25, 2021).

  • Harvard

    Robertson, Sally. 2021. Infliximab Cost. News-Medical, viewed 25 July 2021, https://www.news-medical.net/health/Infliximab-Cost.aspx.

Comments

  1. Mirta Noemi Bravo Mirta Noemi Bravo Argentina says:

    HOLA . NECESITAMOS CON SUMA URGENCIA INFLIXIMAB 160 MG CADA 15 DIAS PARA UN NIÑO DE 4 AÑOS, DIAG . PANCOLITIS . SE DEBE EMPEZAR CON ESTA MEDICACION LO MAS URGENTE NECESITAMOS UNA RESPUESTA DE USTEDES COMO PODEMOS CONSEGUIRLA YA QUE ES MUY CARA . GRACIAS

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.